Literature DB >> 10856272

Angiotensin-(1-7) reduces norepinephrine release through a nitric oxide mechanism in rat hypothalamus.

M M Gironacci1, M Vatta, M Rodriguez-Fermepín, B E Fernández, C Peña.   

Abstract

Angiotensin (Ang)-(1-7) elicits a facilitatory presynaptic effect on peripheral noradrenergic neurotransmission, and because biological responses to the heptapeptide on occasion are tissue specific, the present investigation was undertaken to study its action on noradrenergic neurotransmission at the central level. In rat hypothalamus labeled with [(3)H]-norepinephrine, 100 to 600 nmol/L Ang-(1-7) diminished norepinephrine released by 25 mmol/L KCl. This effect was blocked by the selective angiotensin type 2 receptor antagonist PD 123319 (1 micromol/L) and by the specific Ang-(1-7) receptor antagonist ([D-Ala(7)]Ang-(1-7) (1 micromol/L) but not by losartan (10 nmol/L to 1 micromol/L), a selective angiotensin type 1 receptor antagonist. The inhibitory effect on noradrenergic neurotransmission caused by Ang-(1-7) was prevented by 10 micromol/L N(omega)-nitro-L-arginine methylester, an inhibitor of nitric oxide synthase activity, and was restored by 100 micromol/L L-arginine, precursor of nitric oxide synthesis. Methylene blue (10 micromol/L), an inhibitor of guanylate cyclase considered as the target of nitric oxide action, as well as Hoe 140 (10 micromol/L), a bradykinin B(2)-receptor antagonist, prevented the inhibitory effect of the heptapeptide on neuronal norepinephrine release, whereas no modification was observed in the presence of 0.1 to 10 micromol/L indomethacin, a cyclooxygenase inhibitor. Our results indicate that Ang-(1-7) has a tissue-specific neuromodulatory effect on noradrenergic neurotransmission, being inhibitory at the central nervous system by a nitric oxide-dependent mechanism that involves angiotensin type 2 receptors and local bradykinin production.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10856272     DOI: 10.1161/01.hyp.35.6.1248

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Chronic oral administration of Ang-(1-7) improves skeletal muscle, autonomic and locomotor phenotypes in muscular dystrophy.

Authors:  Rasna Sabharwal; Michael Z Cicha; Ruben D M Sinisterra; Frederico B De Sousa; Robson A Santos; Mark W Chapleau
Journal:  Clin Sci (Lond)       Date:  2014-07       Impact factor: 6.124

2.  Angiotensin-(1-7) does not affect norepinephrine neuronal uptake or catabolism in rat hypothalamus and atria.

Authors:  M M Gironacci; M Rodríguez-Fermepín; M Vatta; B E Fernandez; M Rubio; C Peña
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

Review 3.  ACE2/ANG-(1-7)/Mas pathway in the brain: the axis of good.

Authors:  Ping Xu; Srinivas Sriramula; Eric Lazartigues
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-12-22       Impact factor: 3.619

4.  Angiotensin-(1-7) increases neuronal potassium current via a nitric oxide-dependent mechanism.

Authors:  Rui-Fang Yang; Jing-Xiang Yin; Yu-Long Li; Matthew C Zimmerman; Harold D Schultz
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-27       Impact factor: 4.249

Review 5.  Angiotensin II and angiotensin-1-7 redox signaling in the central nervous system.

Authors:  Matthew C Zimmerman
Journal:  Curr Opin Pharmacol       Date:  2011-01-21       Impact factor: 5.547

Review 6.  The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7).

Authors:  Robson Augusto Souza Santos; Walkyria Oliveira Sampaio; Andreia C Alzamora; Daisy Motta-Santos; Natalia Alenina; Michael Bader; Maria Jose Campagnole-Santos
Journal:  Physiol Rev       Date:  2018-01-01       Impact factor: 37.312

Review 7.  Angiotensin peptides and nitric oxide in cardiovascular disease.

Authors:  Kaushik P Patel; Harold D Schultz
Journal:  Antioxid Redox Signal       Date:  2012-05-21       Impact factor: 8.401

8.  Angiotensin-(1-7) oral formulation improves physical performance in mountain bike athletes: a double-blinded crossover study.

Authors:  Samara Silva de Moura; Adália Táci Pereira Mendes; Francisco de Assis Dias Martins-Júnior; Nádia Lúcia Totou; Daniel Barbosa Coelho; Emerson Cruz de Oliveira; Daisy Motta-Santos; Robson Augusto Souza Dos Santos; Lenice Kappes Becker
Journal:  BMC Sports Sci Med Rehabil       Date:  2021-05-06

Review 9.  Angiotensin-converting enzyme 2: central regulator for cardiovascular function.

Authors:  Huijing Xia; Eric Lazartigues
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

Review 10.  Angiotensin-converting enzyme 2 in the brain: properties and future directions.

Authors:  Huijing Xia; Eric Lazartigues
Journal:  J Neurochem       Date:  2008-11-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.